November 20-21, Professor Marie-Claude Potier, Academician of the French National Academy of Medicine and Research Director at the French National Center for Scientific Research (CNRS), visited Oujiang Laboratory. She tengaging in discussions on clinical research and translational outcomes in neuroscience and pediatrics. Academician Weihong Song , Director of Oujiang Laboratory and Academic Vice President of Wenzhou Medical University, warmly received the delegation.
Academician Marie-Claude Potier serves as Co-Director of the " She is a co-leader of the Alzheimer's Disease and Prion Diseases group at ICM, a founding member of the International Trisomy 21 Research Society (T21RS), and its 2024-2025 President. With nearly 25 years of research on Down syndrome, she is currently developing pharmacological treatments to enhance cognitive abilities in individuals with Down syndrome and studying early-stage Alzheimer's symptoms in this population.
Academician Weihong Song accompanied the visit to Oujiang Laboratory, providing Academician Marie-Claude Potier with a detailed overview of the laboratory's talent team development, scientific research achievements, and technology transfer efforts. Academician Potier expressed high praise for Oujiang Laboratory's advanced construction philosophy, efficient development pace, and comprehensive research support infrastructure.
During her visit, Academician Marie-Claude Potier delivered two insightful academic presentations: “Biomarker Research for Early Detection of Alzheimer's Disease in Down Syndrome” and “Novel Strategies to Reduce Toxic Amyloid in the Brain and Cerebrovascular System of Alzheimer's Disease Patients.” She presented her team's latest advances in studying neuropathological features in individuals with Down syndrome and explored potential novel specific biomarkers that may aid in predicting the development of Alzheimer's disease in this population. Academician Potier introduced a novel therapeutic strategy targeting the cholesterol-binding site of the mutated amyloid precursor protein (APP) binding sites to reduce toxic Aβ peptide production in AD. Together with attending experts, they explored current mainstream mechanisms regarding abnormal Aβ plaque deposition in the brains and periphery of Alzheimer's disease patients, as well as how to utilize cellular models and omics research to study cerebral amyloid angiopathy and related genes.
